Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

China flag China · Delayed Price · Currency is CNY
11.52
-0.13 (-1.12%)
Apr 28, 2026, 3:00 PM CST
Market Cap13.38B +29.8%
Revenue (ttm)10.31B +6.4%
Net Income702.17M +28.4%
EPS0.60 +26.1%
Shares Out1.16B
PE Ratio19.30
Forward PE25.32
Dividend0.21 (1.80%)
Ex-Dividend Daten/a
Volume40,795,134
Average Volume31,361,424
Open11.68
Previous Close11.65
Day's Range11.43 - 11.75
52-Week Range8.66 - 13.06
Beta0.38
RSI62.94
Earnings DateApr 8, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd.... [Read more]

Sector Healthcare
Founded 1956
Employees 7,994
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600267
Full Company Profile

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 2.03% compared to the previous year's 10.34 billion. Earnings were 540.71 million, a decrease of -10.06%.

Financial Statements